Invitae (NYSE:NVTA) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the medical research company’s stock.

Invitae Stock Performance

NVTA stock opened at $0.00 on Monday. The stock has a market cap of $534,020.00, a P/E ratio of 0.00 and a beta of 1.59. The stock’s fifty day simple moving average is $0.02 and its two-hundred day simple moving average is $0.37. Invitae has a 1-year low of $0.02 and a 1-year high of $0.02.

Institutional Trading of Invitae

Several hedge funds have recently made changes to their positions in the company. Veritable L.P. bought a new stake in shares of Invitae during the 1st quarter valued at $25,000. SG Americas Securities LLC bought a new position in Invitae in the 3rd quarter worth about $29,000. Captrust Financial Advisors increased its stake in Invitae by 501.1% in the 2nd quarter. Captrust Financial Advisors now owns 14,396 shares of the medical research company’s stock worth $35,000 after acquiring an additional 12,001 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Invitae by 113.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 26,626 shares of the medical research company’s stock worth $35,000 after acquiring an additional 14,137 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new position in Invitae in the 4th quarter worth about $35,000. 61.28% of the stock is currently owned by institutional investors.

Invitae Company Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.